NCT00739466 (BLAST) is a Phase 2 clinical trial of Liposomal Alendronate in Coronary Artery Stenosis, sponsored by BIOrest Ltd..

Who is sponsoring NCT00739466?

NCT00739466 is sponsored by BIOrest Ltd..

What drugs are being tested in NCT00739466?

Interventions in NCT00739466: Liposomal Alendronate, Liposomal Alendronate, Saline infusion (placebo).

What condition does NCT00739466 study?

NCT00739466 studies Coronary Artery Stenosis.

Is NCT00739466 still recruiting?

NCT00739466 is currently completed. Last updated 17 January 2016.

Last reviewed 2016-01-17 · How we verify

NCT00739466: BLAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation

Completed Phase 2 Last updated 17 January 2016

What this trial tests

Phase 2 trial testing Liposomal Alendronate in Coronary Artery Stenosis in 226 participants. Completed in 1 December 2015.

Timeline

1 September 2008

Primary endpoint
1 December 2015

1 December 2015

Quick facts

Lead sponsor	BIOrest Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	226
Start date	1 September 2008
Primary completion	1 December 2015
Estimated completion	1 December 2015
Sites	12 locations across Israel

Drugs / interventions tested

Liposomal Alendronate — full drug profile →
Liposomal Alendronate — full drug profile →
Saline infusion (placebo)

Conditions studied

Coronary Artery Stenosis — all drugs for Coronary Artery Stenosis →

Sponsor

BIOrest Ltd. — full company profile →

Who can join

Adults 18 to 80, any sex, with Coronary Artery Stenosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

In-stent late loss: measured at 6 months post-procedure as determined by quantitative coronary angiography (QCA).
Time frame: 6 months post-procedure

Sponsor's own description

The main objective of this study is to assess the safety and efficacy of Liposomal Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a population undergoing PCI with implantation of a bare metal stent. Study hypothesis: Liposomal Alendronate will reduce in-stent restenosis as compared to placebo.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Perspectives and opportunities for nanomedicine in the management of atherosclerosis.
Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. · · 2011 · cited 286× · PMID 22015921 · DOI 10.1038/nrd3578
Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients.
Chariou PL, Ortega-Rivera OA, Steinmetz NF. · · 2020 · cited 101× · PMID 32125825 · DOI 10.1021/acsnano.0c00173
Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.
Xu H, Li S, Liu YS. · · 2022 · cited 52× · PMID 35817770 · DOI 10.1038/s41392-022-01082-z
Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial.
Banai S, Finkelstein A, Almagor Y, Assali A, et al · · 2013 · cited 22× · PMID 23351827 · DOI 10.1016/j.ahj.2012.10.023
Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.
Yang C, Mo L, Zhang G, Dai Y, et al · · 2026 · cited 3× · PMID 41069764 · DOI 10.1016/j.bioactmat.2025.09.023

Verify or expand the search:

Other recruiting trials for Coronary Artery Stenosis

Currently open trials in the same condition.

NCT06177743 — IRIS-Coroflex NEO Cohort · recruiting
NCT04893291 — Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II · NA · active not recruiting
NCT05133843 — Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Impl · NA · recruiting
NCT04604197 — ANGiographic Evaluation of Left Main Coronary Artery INtErvention · NA · active not recruiting
NCT04192747 — The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00739466 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BIOrest Ltd.
Last refreshed: 17 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00739466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing